1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Global Markets for Diabetes Therapeutics and Diagnostics -- Focus on Asia

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for drugs used in the treatment of diabetes and for devices and instruments used in the diagnosis and monitoring of diabetes. Special emphasis is given to major forces contributing to the vigorous growth of the diabetes market. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2017. These forecasts are based on epidemiological data and projections, as well as on information about R&D trends and differential market potential on a country-by-country basis. Health care policies, demographics, and the wider economic environment are also taken into account.

REASONS FOR DOING THE STUDY

It is widely recognized that the prevalence of the most common type of diabetes mellitus, Type 2, is now reaching epidemic proportions all over the world. Cases of Type 1 diabetes are also on the rise, although to a less spectacular degree. These trends are of great concern, not only to the individuals affected, but also to governments and providers of health care. Indeed, the economic consequences of diabetes are vast, involving not only the direct burden of managing the disease but also the common and often catastrophic complications such as cardiovascular disease, peripheral neuropathy, and blindness.

Prompt diagnosis and effective treatment of diabetes are essential, not optional, priorities for governments and health care agencies. The already large market for diabetes monitoring and treatment will certainly grow in line with increasing incidence and with improvements in diagnosis. Thus diabetes is of great commercial significance to the suppliers of drugs used in treatment and to the suppliers of devices needed for disease monitoring.

Among the information needs of companies in this field is an accurate and up-to-date assessment of the current extent of the diabetes epidemic, its likely evolution over the next five years, and the impact of drugs and technical developments now in the pipeline.

SCOPE OF REPORT

This report discusses the implications of the above-mentioned trends in the context of the current size and growth of the diabetes market, discussed both in global terms and in terms of the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on merger and acquisition (M&A) activity. Five-year global sales forecasts are provided for main drug and device categories, and breakdowns are provided for several national markets.

A comprehensive refresher course on diabetes is provided as an appendix.

MARKET ANALYSES AND FORECASTS

The dimensions of the surging diabetes epidemic can be witnessed in stark outline against previous smaller estimates only a few years back. Increased awareness of this “modern plague” has led naturally to improved and more frequent testing practices. This new awareness has also led to improved treatment compliance by patients. Added to these are the more expensive therapies and increased penetration of continuous glucose monitoring (CGM) approaches, which all combine to build a public health menace of accelerating proportions.

For the purpose of market analyses in this report, the global market is defined as 13 countries which together make up over 80% of the total diabetes universe. These countries are the U.S., Canada, Brazil, Mexico, China, India, Japan, Russia, Germany, France, Italy, Spain and the U.K.

Market figures are based on revenues at the manufacturer level and are projected at 2012-dollar value without attempting to predict the effect of inflation/deflation. Therapeutic categories discussed include insulins and oral hypoglycemic agents, devices including blood glucose monitors and accessories, and software aids to self-management of diabetes by patients.

METHODOLOGY

Primary research for this report included interviews with leading individuals in relevant companies and medical associations; primary sources of published data include epidemiological and economic studies, company annual reports, SEC filings, and government publications. Secondary sources consisted of literature searches, industry journals, and other commercial publications. Data for market estimates and forecasts were pooled from a range of sources, critically assessed by BCC.

INTENDED AUDIENCE

This report is designed to satisfy the information needs of a wide variety of individuals involved in the diabetes marketplace, including company senior management executives seeking to base their strategic decisions on the best available information with regard to market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning, and sales departments who need readable, comprehensive, and up-to-date background information on the marketplace in which they are operating.

INFORMATION SOURCES

Sources of information included marketing strategists, industry executives, government and professional agencies, and surveys of physicians. Company annual reports and SEC filings, journal articles, and data from health care institutions were also mined, as well as publications of relevant associations such as the International Diabetes Federation and the American and British Diabetic Associations.

ANALYST CREDENTIALS

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the diabetes marketplace covering both therapeutic and monitoring aspects.

Table Of Contents

Global Markets for Diabetes Therapeutics and Diagnostics -- Focus on Asia
TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
SCOPE OF REPORT 1
MARKET ANALYSES AND FORECASTS 2
METHODOLOGY 2
INTENDED AUDIENCE 2
INFORMATION SOURCES 2
ANALYST CREDENTIALS 2
RELATED REPORTS 3
BCC ONLINE SERVICES 3
DISCLAIMER 3
CHAPTER 2 SUMMARY 5
THE DIABETES MARKET 5
LEADING COMPANIES 5
SUMMARY TABLE DIABETES MARKET BREAKDOWN BY REGIONS, THROUGH 2017 ($
BILLIONS) 6
SUMMARY FIGURE DIABETES MARKET EVOLUTION BY REGION, 2011-2017 ($ BILLIONS) 6
CHAPTER 3 OVERVIEW 8
DIABETES BASICS 8
STRUCTURE OF THE DIABETES MARKET 8
DRIVERS FOR GROWTH 8
RISING PREVALENCE 8
TABLE 1 GLOBAL AND REGIONAL DIABETES PREVALENCE, 2011 AND 2017 (CASES IN
MILLIONS) 8
NEW TECHNOLOGY 9
RATE OF MARKET GROWTH 10
CURRENT TREATMENT OF DIABETES 10
INSULIN 10
Insulin Administration Devices 10
ORAL ANTIDIABETIC DRUGS 11
MONITORING DEVICES FOR DIABETES 11
TABLE 2 TOTAL DIABETES MARKET IN 2012 ($ BILLIONS) 11
REGIONAL SEGMENTATION 11
TABLE 3 ADULT DIABETES MARKET BY REGION (MILLIONS/%) 12
MARKET GROWTH 12
THE DIABETES INDUSTRY 12
PHARMACEUTICAL COMPANIES 12
MEDICAL DEVICE COMPANIES 13
CHAPTER 4 PRODUCTS AND SUPPLIERS 15
INSULIN 15
HISTORY 15
Bovine and Porcine Insulin 16
Humanized Insulin 16
COMPANIES SUPPLYING INSULIN 17
Eli Lilly 17
Sanofi 17
Novo Nordisk 17
Some Other Suppliers 17
Wockhardt Limited: India 17
BioconB: India 18
Shreya Life Sciences: India 18
Diosynth: the Netherlands 18
TABLE 4 MAJOR BRANDS OF INSULIN 18
INSULIN DELIVERY 19
SYRINGES 19
INSULIN SYRINGE MANUFACTURERS 19
Becton Dickinson 19
Owen Mumford 20
Terumo 20
B. Braun 20
PENS 20
TABLE 5 INSULIN PENS 21
MANUFACTURERS OF INSULIN PENS 21
Novo Nordisk 21
Owen Mumford 22
Other Makers 22
INJECTORS 22
INJECTOR MANUFACTURERS 23
Activa Brand Products 23
Antares Pharma 23
Bioject 23
MediCool Inc. 23
Owen Mumford 24
Palco Labs Inc. 24
Rosch AG Medizintechnik 24
INSULIN PUMPS 24
What Is an Insulin Pump? 24
The Infusion Set 25
Candidates for Pump Therapy 25
COMPANIES SUPPLYING INSULIN PUMPS 26
Animas Corp. 26
Sooil Development Co. 27
Medtronic MiniMed 27
Nipro Diabetes Systems 27
Roche Insulin Delivery Systems 27
Insulet 27
Tandem Diabetes Care 28
TABLE 6 INSULIN PUMPS 28
Problems with Pumps-or Users? 28
ORAL HYPOGLYCEMIC DRUGS 29
SULFONYLUREAS 29
TABLE 7 SULFONYLUREAS 29
BIGUANIDES 30
ALPHA-GLUCOSIDASE INHIBITOR 30
GLITAZONES 30
PRANDIAL GLUCOSE REGULATORS 30
GLP-1 ANALOGS; ALSO KNOWN AS INCRETIN MIMETICS 31
AMYLIN MIMETIC 31
TABLE 8 ORAL HYPOGLYCEMICS 32
DIAGNOSIS AND MONITORING 32
THE ROLE OF SELF-MONITORING 32
SMBG Frequency 33
BLOOD GLUCOSE MONITORING DEVICES: SUPPLIERS AND PRODUCTS 33
Lancets 34
TABLE 9 INTERNATIONAL SUPPLIERS OF BLOOD LANCETS 34
BLOOD-SAMPLING DEVICES 34
Bayer Diagnostics 34
Becton Dickinson 35
Cell Robotics 35
LifeScan 35
Roche Diagnostics 35
BLOOD GLUCOSE MONITORS 35
77 Elektronika Kft 35
Abbott Laboratories 36
Acon Laboratories Inc. 36
AgaMatrix Inc. 36
Apex Biotechnology Corp. 37
Arkray USA 37
Aventir Biotech LLC 37
Bayer Corp. 37
Belbiosens 38
Diagnostic Devices Inc. 38
Eumed Biotechnology Co. Ltd. 38
GlucoPlus Inc. 38
HMD Bio Medical 38
Health and Life Co. 38
HemoCue AB 39
Home Diagnostics Inc. 39
Hypoguard 39
i-SENS Inc. 39
LifeScan Inc. 39
Medtronic 39
Menarini Diagnostics 40
National Diagnostic Products 40
Novabiomedical Corp. 40
Roche 40
TaiDoc Technology Corp. 41
US Diagnostics Inc. 41
GLUCOSE METER ACCURACY 41
OTHER TESTING APPROACHES 42
HEMOGLOBIN A1C 42
Hemoglobin A1c Meters 42
Hemoglobin A1c Kits 43
SOFTWARE AIDS TO DIABETES MONITORING 44
AIDA On-Line 44
Bayer Care: Blood Sugar Log 44
Body Sigma 44
Dailyrating 44
DiabetEASE 44
Diabetes Assistant 45
Diabetes Homecare Center 45
Ecivon 45
HealthEngage Diabetes 45
Lifeclinic 46
PlasmaGlucose 46
Symcare 46
CHAPTER 5 NEW DEVELOPMENTS IN DIABETES 48
APPROACHES BASED ON CURRENT TECHNOLOGY 48
NOVEL INSULIN DELIVERY TECHNOLOGY 48
Oral-Lyn 48
Oramed 48
Medingo Micro-Pump Patch 48
Inhaled Insulin 49
Transdermal Approach 49
IMPROVED ORAL ANTIDIABETIC DRUGS 50
Dutogliptin 50
Byetta LAR 50
Lixisenatide 50
NEW DEVELOPMENTS IN GLUCOSE TESTING 51
Continuous Glucose Monitoring (CGM) 51
Reimbursement 52
Noninvasive Monitoring 52
TABLE 10 SELECTED COMPANIES DEVELOPING NONINVASIVE GLUCOSE MONITORING 55
Integrated Testing 56
ARTIFICIAL PANCREAS 57
Roche 57
Abbott 58
Novo Nordisk/LifeScan 58
Animas 58
RADICAL APPROACHES 59
ALTERNATIVES TO INSULIN 59
IMMUNOTHERAPY 60
TRANSPLANTATION 60
CELL AND STEM CELL THERAPIES 61
GENE THERAPY 62
Gene Therapy Approaches for Expressing Insulin 62
Gene Therapy Approaches for Immunomodulation 62
Gene Therapy Approaches for Cell-Based Therapies 62
A NEW AGE OF MOBILITY IN DIABETES MANAGEMENT 63
THE IMPACT OF NEW DEVELOPMENTS ON THE DIABETES MARKET 64
CHAPTER 6 THE GLOBAL DIABETES MARKET 67
MARKET COMPONENTS 67
SIZE 67
TABLE 11 GLOBAL DIABETES MARKET, 2011 ($ BILLIONS) 67
GROWTH 68
MARKET ANALYSIS BY PRODUCT CATEGORY 68
INSULINS AND INSULIN DELIVERY DEVICES 68
Major Suppliers 69
TABLE 12 GLOBAL SALES OF LEADING INSULIN PRODUCTS, 2011 ($ MILLIONS) 69
OTHER ANTIDIABETIC DRUGS 69
Major Suppliers 69
TABLE 13 SALES OF OTHER ANTIDIABETIC DRUGS, 2011 ($ MILLIONS) 70
INSULIN PUMPS 70
TABLE 14 DIABETES MARKET BREAKDOWN BY REGION, THROUGH 2017 ($ BILLIONS) 71
MONITORING PRODUCTS 71
Major Suppliers 71
TABLE 15 LEADING SUPPLIERS OF GLUCOSE MONITORING PRODUCTS, 2011 (MILLIONS/%) 71
TRENDS 71
REGIONAL SEGMENTATION 72
TABLE 16 RISING PREVALENCE OF DIABETES BY REGION, THROUGH 2017 (CASES IN
MILLIONS) 72
NATIONAL MARKETS 72
North America 73
TABLE 17 TOTAL DIABETES MARKET FOR CANADA AND THE U.S., THROUGH 2017 ($
BILLIONS) 73
South and Central America 74
TABLE 18 TOTAL DIABETES MARKET FOR MEXICO AND BRAZIL, THROUGH 2017 ($
BILLIONS) 74
Europe 74
TABLE 19 MAJOR EUROPEAN ECONOMIES: TOTAL DIABETES MARKET, THROUGH 2017 ($
BILLIONS) 75
Asia 75
TABLE 20 MAJOR ASIAN COUNTRIES: TOTAL DIABETES MARKET, THROUGH 2017 ($
BILLIONS) 75
CHAPTER 7 THE ASIAN MARKET 77
CHINA 77
VITAL STATISTICS 77
HEALTH AND HEALTH CARE 77
CHINA'S PHARMACEUTICAL MARKET 78
DOMESTIC INDUSTRY 79
FOREIGN COMPANY INVOLVEMENT 80
IMPORTANCE OF RandD 81
CHALLENGES 81
MARKET TRENDS 81
REGULATORY CHANGES 82
THE DIABETES MARKET 83
TABLE 21 PREVALENCE OF DIABETES IN CHINA, THROUGH 2017 (CASES IN MILLIONS) 83
TABLE 22 CHINA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 84
TABLE 23 CHINA: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 84
INDIA 84
VITAL STATISTICS 84
HEALTH AND HEALTH CARE 84
GROWING AFFLUENCE-CHANGING MEDICAL NEEDS 85
REGULATORY CHANGES 85
INDIA'S PHARMACEUTICAL MARKET 85
DEMOGRAPHIC FACTORS 85
PHARMA INDUSTRY 86
PATENT REFORM 86
THE DIABETES MARKET 87
TABLE 24 PREVALENCE OF DIABETES IN INDIA, THROUGH 2017 (CASES IN MILLIONS) 87
TABLE 25 INDIA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 87
TABLE 26 INDIA: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 88
JAPAN 88
VITAL STATISTICS 88
HEALTH AND HEALTH CARE 88
JAPAN'S PHARMACEUTICAL MARKET 89
TABLE 27 TOP SIX JAPANESE PHARMA COMPANIES, 2010 89
THE DIABETES MARKET 90
TABLE 28 PREVALENCE OF DIABETES IN JAPAN, THROUGH 2017 (CASES IN MILLIONS) 91
TABLE 29 JAPAN: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 91
TABLE 30 JAPAN: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 91
CHAPTER 8 COMPANY PROFILES 93
LEADING COMPANIES 93
ABBOTT LABORATORIES 93
Overview 93
ABBOTT DIABETES CARE, INC. 94
BAYER AG 94
Overview 94
Diabetes Products 95
BECTON DICKINSON 95
Overview 95
Diabetes Products 96
BRISTOL-MYERS SQUIBB 96
Overview 96
Problems with Generics 96
Diabetes Products 96
Pipeline 97
ELI LILLY AND CO. 97
Overview 97
Diabetes Products 97
Pipeline 98
GLAXO SMITHKLINE 98
Overview 98
Diabetes Products 98
Pipeline 99
JOHNSON and JOHNSON 99
Overview 99
Diabetes Products 99
Pipeline 100
MEDTRONIC 100
Overview 100
Diabetes Products 101
Pipeline 101
MERCK and CO. LTD. 101
Diabetes 102
SmartCells 102
MERCK KGAA 103
Overview 103
Diabetes Products 103
NOVARTIS INTERNATIONAL AG 104
Overview 104
Diabetes Products 104
Research 104
NOVO NORDISK A/S 105
Overview 105
Diabetes Products 105
Pipeline 106
TABLE 31 NOVO NORDISK DIABETES PRODUCT PIPELINE 107
ROCHE 107
Overview 107
Diabetes Products 108
Blood Glucose Monitoring Systems 108
Diabetes Data Management 109
Insulin Pump Systems 109
Lancet Devices 109
Other 110
Pipeline 110
SANOFI 110
Overview 110
Diabetes Products 111
TAKEDA 111
Overview 111
Pipeline 112
TABLE 32 DIABETES PRODUCTS IN DEVELOPMENT BY TAKEDA 112
OTHER COMPANIES 113
77 ELEKTRONIKA CO., LTD. 113
AGAMATRIX, INC. 113
ANIMAS CORP. 114
BIO-IMPEDANCE GENERAL LTD. 114
DEBIOTECH S.A. 115
INLIGHT SOLUTIONS, INC. 115
LIFESCAN, INC. 116
MANNKIND CORP. 116
A. MENARINI DIAGNOSTICS S.R.L. 117
NIPRO CORP. 3-9-3, 117
OWEN MUMFORD LTD. 118
PALCO LABS, INC. 119
PRODIGY DIABETES CARE LLC 119
TERUMO CORP. 120
TRANSITION THERAPEUTICS INC. 120
CHAPTER 9 APPENDIX I: ABOUT DIABETES 122
BLOOD SUGAR REGULATION 122
INSULIN 122
TYPE 1 DIABETES 123
TYPE 2 DIABETES 123
GESTATIONAL DIABETES 124
OBESITY-RELATED TYPE 2 DIABETES IN CHILDREN 124
MATURE-ONSET DIABETES OF THE YOUNG (MODY) 125
OTHER DIABETIC STATES 125
LATENT AUTOIMMUNE DIABETES (LADA) 125
PREDIABETES 125
DIAGNOSIS 126
GLUCOSE TESTS 126
OFFICIAL CRITERIA 126
DIFFERENTIAL DIAGNOSIS 126
TYPE 1 DIABETES 126
TYPE 2 DIABETES 127
CURRENT TREATMENT 127
TYPE 1 DIABETES 127
TYPE 2 DIABETES 127
Sulfonylureas 128
Biguanides 128
Alpha-Glucosidase Inhibitors 128
Glitazones (Thiazolidinediones) 129
Prandial Glucose Regulators 129
Incretin Mimetics 129
Dipeptidyl Peptidase 4 (DPP-4) Inhibitors 129
DIET 129
MONITORING DIABETES 129
BLOOD SUGAR CONTROL 129
THE DIABETES CONTROL AND COMPLICATIONS TRIAL (DCTT) 130
GLYCATED HEMOGLOBIN (HBA1C) 131
FRUCTOSAMINE 132
PREVALENCE OF DIABETES 132
TYPE 1 133
TYPE 2 133
DIABETIC COMPLICATIONS 133
RETINOPATHY 134
NEUROPATHY 134
NEPHROPATHY 135
INCREASED MORTALITY RISK 135
METABOLIC SYNDROME 135
CHAPTER 10 APPENDIX 2: GLOSSARY 138
TABLE 33 GLOSSARY 138

LIST OF TABLES
SUMMARY TABLE DIABETES MARKET BREAKDOWN BY REGIONS, THROUGH 2017 ($
BILLIONS) 6
TABLE 1 GLOBAL AND REGIONAL DIABETES PREVALENCE, 2011 AND 2017 (CASES IN
MILLIONS) 8
TABLE 2 TOTAL DIABETES MARKET IN 2012 ($ BILLIONS) 11
TABLE 3 ADULT DIABETES MARKET BY REGION (MILLIONS/%) 12
TABLE 4 MAJOR BRANDS OF INSULIN 18
TABLE 5 INSULIN PENS 21
TABLE 6 INSULIN PUMPS 28
TABLE 7 SULFONYLUREAS 29
TABLE 8 ORAL HYPOGLYCEMICS 32
TABLE 9 INTERNATIONAL SUPPLIERS OF BLOOD LANCETS 34
TABLE 10 SELECTED COMPANIES DEVELOPING NONINVASIVE GLUCOSE MONITORING 55
TABLE 11 GLOBAL DIABETES MARKET, 2011 ($ BILLIONS) 67
TABLE 12 GLOBAL SALES OF LEADING INSULIN PRODUCTS, 2011 ($ MILLIONS) 69
TABLE 13 SALES OF OTHER ANTIDIABETIC DRUGS, 2011 ($ MILLIONS) 70
TABLE 14 DIABETES MARKET BREAKDOWN BY REGION, THROUGH 2017 ($ BILLIONS) 71
TABLE 15 LEADING SUPPLIERS OF GLUCOSE MONITORING PRODUCTS, 2011 (MILLIONS/%) 71
TABLE 16 RISING PREVALENCE OF DIABETES BY REGION, THROUGH 2017 (CASES IN
MILLIONS) 72
TABLE 17 TOTAL DIABETES MARKET FOR CANADA AND THE U.S., THROUGH 2017 ($
BILLIONS) 73
TABLE 18 TOTAL DIABETES MARKET FOR MEXICO AND BRAZIL, THROUGH 2017 ($ BILLIONS) 74
TABLE 19 MAJOR EUROPEAN ECONOMIES: TOTAL DIABETES MARKET, THROUGH 2017 ($
BILLIONS) 75
TABLE 20 MAJOR ASIAN COUNTRIES: TOTAL DIABETES MARKET, THROUGH 2017 ($
BILLIONS) 75
TABLE 21 PREVALENCE OF DIABETES IN CHINA, THROUGH 2017 (CASES IN MILLIONS) 83
TABLE 22 CHINA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 84
TABLE 23 CHINA: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 84
TABLE 24 PREVALENCE OF DIABETES IN INDIA, THROUGH 2017 (CASES IN MILLIONS) 87
TABLE 25 INDIA: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 87
TABLE 26 INDIA: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 88
TABLE 27 TOP SIX JAPANESE PHARMA COMPANIES, 2010 89
TABLE 28 PREVALENCE OF DIABETES IN JAPAN, THROUGH 2017 (CASES IN MILLIONS) 91
TABLE 29 JAPAN: DIABETES MEDICATIONS MARKET, THROUGH 2017 ($ BILLIONS) 91
TABLE 30 JAPAN: DIABETES DEVICES MARKET, THROUGH 2017 ($ BILLIONS) 91
TABLE 31 NOVO NORDISK DIABETES PRODUCT PIPELINE 107
TABLE 32 DIABETES PRODUCTS IN DEVELOPMENT BY TAKEDA 112
TABLE 33 GLOSSARY 138

LIST OF FIGURES
SUMMARY FIGURE DIABETES MARKET EVOLUTION BY REGION, 2011-2017 ($ BILLIONS) 6

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Markets for Diabetes Therapeutics and Diagnostics

Global Markets for Diabetes Therapeutics and Diagnostics

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Analyze the market for drugs used in the treatment of diabetes, it's technology and the industry as a whole - Identify important trends and provide sales forecasts by product categories ...

European Market Overview for Diabetes Monitoring, Treatment and Drug Delivery 2016 - MedView

European Market Overview for Diabetes Monitoring, Treatment and Drug Delivery 2016 - MedView

  • $ 4995
  • Industry report
  • September 2016
  • by iData Research, Inc.

The European diabetes diagnosis, treatment and drug delivery market increased in 2015 and growth is expected to persist over the forecast period. Market growth will be driven by the growing prevalence ...

Diabetic Gastroparesis  - Market Insights, Epidemiology and Market Forecast-2023

Diabetic Gastroparesis  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Diabetic Gastroparesis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Diabetic Gastroparesis fo ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.